Lower Drug Cost of Successfully Treating Patients with Type 2 Diabetes to Targets with Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in Japan: A Short-Term Cost-Effectiveness Analysis
posted on 2020-08-28, 12:42authored byAtaru Igarashi, Barnaby Hunt, Lars Wilkinson, Jakob Langer, Richard F. Pollock
The above Summary Slide represents the opinions of
the authors. For a full list of declarations, including funding and author
disclosure statements, please see the full text online (see “read the
peer-reviewed publication” opposite).